Phenogen Sciences

Phenogen Sciences is a molecular diagnostics company and the U.S. subsidiary of Genetic Technologies Limited. The company specializes in personalized health risk assessment tools that integrate genetic markers with clinical risk factors to predict the likelihood of developing serious diseases. Its lead product, BREVAGenplus, is a clinically validated risk assessment test for sporadic breast cancer that helps physicians tailor screening and prevention plans. Phenogen Sciences also offers the geneType suite of tests, which provides risk stratification for colorectal cancer, prostate cancer, melanoma, and type 2 diabetes. By utilizing polygenic risk scores, the company aims to move healthcare from a reactive to a proactive model. Phenogen Sciences operates within the U.S. market to provide actionable genomic information to healthcare providers and patients.